EP. 2 Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
EP. 7 The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel
Unmet needs and emerging solutions in MRI-guided prostate cancer careByPreston C. Sprenkle, MDJune 22nd 2026
The UroOnc Minute: Keeping Patients Engaged in Active Surveillance, With Lourdes Guerrios-Rivera, MD, MScByAdam B. Weiner, MD,Lourdes Guerrios Rivera, MD, MScJune 19th 2026
Andrew J. Armstrong, MD, MSc, discusses study of chemoimmunotherapy in NEPC/AVPCByAndrew J. Armstrong, MD, MScJune 18th 2026
Behind the FDA approval of capivasertib for mHSPC, with Daniel J. George, MDByDaniel J. George, MD,Hannah ClarkeJune 17th 2026